Loading...
Loading...
Generating destination analysis
Market Cap
$800M
P/E
N/A
Revenue Growth
+120.0%
Gross Margin
N/A
ROE
N/A
As a small-cap healthcare company trading on the NASDAQ, Nano-X Imaging has established itself, with direct, concentrated exposure to the biotech and genomics theme. Disruptive medical imaging company with novel cold-cathode X-ray technology at fraction of cost. With a $0.8B market capitalization and no current profitability, the company demonstrates exceptional revenue growth at +120% year-over-year.
Expert analysis and coverage for Nano-X Imaging
Or unlock everything now with Compass, $9/moPrice vs 200DMA
DMA Convergence
50 DMA
200 DMA
Eli Lilly and Company
Pharma giant leading the GLP-1 revolution with Mounjaro and Zepbound weight-loss drugs.
DexCom Inc.
Continuous glucose monitoring leader expanding beyond diabetes management.
Regeneron Pharmaceuticals
Biotech powerhouse with strong antibody pipeline and Dupixent franchise.
Alnylam Pharmaceuticals
RNA interference therapeutics leader with approved treatments for rare diseases.